Fintel reports that on October 2, 2023, Citigroup maintained coverage of Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral recommendation.
Analyst Price Forecast Suggests 96.80% Upside
As of August 31, 2023, the average one-year price target for Tandem Diabetes Care is 43.28. The forecasts range from a low of 30.30 to a high of $65.10. The average price target represents an increase of 96.80% from its latest reported closing price of 21.99.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Tandem Diabetes Care is 909MM, an increase of 14.96%. The projected annual non-GAAP EPS is -0.55.
What is the Fund Sentiment?
There are 534 funds or institutions reporting positions in Tandem Diabetes Care. This is a decrease of 58 owner(s) or 9.80% in the last quarter. Average portfolio weight of all funds dedicated to TNDM is 0.10%, a decrease of 31.01%. Total shares owned by institutions decreased in the last three months by 2.86% to 79,186K shares. 
The put/call ratio of TNDM is 0.77, indicating a bullish outlook.
What are Other Shareholders Doing?
Capital World Investors holds 6,486K shares representing 9.97% ownership of the company. In it's prior filing, the firm reported owning 5,957K shares, representing an increase of 8.16%. The firm decreased its portfolio allocation in TNDM by 38.77% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 4,532K shares representing 6.96% ownership of the company. In it's prior filing, the firm reported owning 4,690K shares, representing a decrease of 3.50%. The firm decreased its portfolio allocation in TNDM by 43.46% over the last quarter.
SMCWX - SMALLCAP WORLD FUND INC holds 4,525K shares representing 6.95% ownership of the company. In it's prior filing, the firm reported owning 3,996K shares, representing an increase of 11.70%. The firm decreased its portfolio allocation in TNDM by 35.20% over the last quarter.
Eminence Capital holds 3,118K shares representing 4.79% ownership of the company. In it's prior filing, the firm reported owning 2,470K shares, representing an increase of 20.78%. The firm decreased its portfolio allocation in TNDM by 29.51% over the last quarter.
Bellevue Group holds 2,093K shares representing 3.22% ownership of the company. In it's prior filing, the firm reported owning 1,794K shares, representing an increase of 14.29%. The firm increased its portfolio allocation in TNDM by 8.24% over the last quarter.
Tandem Diabetes Care Background Information
(This description is provided by the company.)
Tandem Diabetes Care, Inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem's flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
